Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | Clinical presentation and management of paraneoplastic neurological syndromes

Divyanshu Dubey, MBBS, Mayo Clinic, Rochester, MN, shares the details of a review of paraneoplastic neurological syndromes (PNS), recently published in Therapeutic Advances in Neurological Disorders. PNS are a group of neurological disorders resulting from autoimmune responses mounted against the nervous system during an antitumor immune response. Onconeural antigens expressed by the tumor and released after cell death, are also expressed in the nervous system, leading to autoimmune attack. The review discusses the various classic and non-classic syndromes that occur, neural-specific antibodies with oncological association, and immunotherapy-based management of PNS. This interview took place during the ACTRIMS Forum 2021.

Disclosures

Dr. Dubey has consulted for UCB, Immunovant and Astellas Pharma. All compensation for consulting activities is paid to Mayo Clinic. He has a patent pending for KLHL 11-IgG and LUZP4-IgG as markers of neurological autoimmunity and germ cell tumors.